IP Library Granted Patent US 9,861,604
Granted Patent B2
US 9,861,604 · App. 14/305,811 · Granted Jan 9, 2018

Patent

Inventors: Allan Sik Yin Lau (Hong Kong, CN); Lai Hung Cindy Yang (Hong Kong, CN); Stanley Chi Chung Chik (Hong Kong, CN)
Assignees: BAGI RESEARCH LIMITED; VERSITECH LIMITED
A61K31/231C11B1/10C11C1/002Y02P20/582
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,861,604
App. No.
14/305,811
Granted
Jan 9, 2018
Kind
B2
Abstract

The subject invention provides efficient and convenient methods of isolating 9-oxo-10E, 12E-octadecadienoic acid methyl ester (9-KODE methyl ester) from C. versicolor . In addition, the subject invention provides therapeutic uses of Coriolus versicolor extracts, biologically-active chemical substituents isolated from C. versicolor , as well as 9-KODE methyl ester and related compounds. In a preferred embodiment, the subject invention can be used to inhibit the metastatic spread of cancer cells.

Claims (6)

1. A method for treating cancer or a tumor, comprising administering, to a subject in need of such treatment, an effective amount of a composition comprising 9-oxo-10E, 12E-octadecadienoic acid methyl ester, or a salt thereof, wherein the cancer or tumor is selected from the group consisting of glioblastoma, breast carcinoma, and lung carcinoma.

2. The method of claim 1 , wherein the subject is a human.

3. A method for treating cancer or a tumor, comprising administering, to a subject in need of such treatment, an effective amount of a composition comprising 9-oxo-10E, 12E-octadecadienoic acid methyl ester, or a salt thereof, wherein the cancer is metastatic cancer and the administration of the composition is used to reduce cancer metastasis.

4. The method of claim 3 , wherein the subject is a human.

5. The method according to claim 1 , wherein the compound inhibits the expression of MMP3.

6. The method according to claim 1 , wherein the compound reduces TNF-α, wherein the compound reduces TNF-α production in tumor cells.

Assignments (2)
CHANGE OF NAME Recorded Jan 5, 2015
From: PURAPHARM COMPANY LIMITED
To: BAGI RESEARCH LIMITED
Reel/Frame 034630/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2015
From: LAU, ALLAN SIK YIN; LAU, MAUREEN; LAU, JONATHAN SEE HAN; YANG, LAI HUNG CINDY; CHIK, STANLEY CHI CHUNG
To: PURAPHARM COMPANY LIMITED; VERSITECH LIMITED
Reel/Frame 034612/0652 →
Continuity (3)
Division 13804103 · Mar 14, 2013
Provisional Application 61622846 · Apr 11, 2012
Related Publication 20140364499A1 · Dec 11, 2014